NCT05581719 - A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions

Solid TumorPeritoneal MetastasesPeritoneal Cancer

Interventions

DRUG

Allocetra-OTS

Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.

DRUG

Nivolumab

Immune checkpoint inhibitor (anti-PD-1 antibody)

DRUG

Tislelizumab

Immune checkpoint inhibitor (anti-PD-1 antibody)

Trial Locations (6)

Unknown

Rambam Medical Center, Haifa

Hadassah Medical Center, Jerusalem

Sheba Medical Center, Ramat Gan

Sourasky Medical Center, Tel Aviv

Clínica Universidad de Navarra, Madrid

NEXT Madrid, Madrid